Latest On iBio, Inc (IBIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-05 23:34 EST | News | iBio finds new panel of CD3 T-cell binding antibodies | N/A |  |
| 2023-02-17 04:10 EST | News | iBio shares more than double in value after hours on new immuno-oncology target program | N/A | |
| 2022-12-07 14:33 EST | News | iBio shares slide on pricing $3.5M securities offering | N/A | |
| 2022-12-06 20:47 EST | News | iBio intends to offer and sell shares, purchase warrants in underwritten public offering | N/A | |
| 2022-12-05 09:44 EST | News | iBio's CEO Thomas F. Isett departs | N/A | |
About iBio, Inc (IBIO):
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bi read more...o analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.
General
- Name iBio, Inc
- Symbol IBIO
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 43
- Last Split Factor1:10
- Last Split Date2018-06-11
- Fiscal Year EndJune
- IPO Date2008-08-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.ibioinc.com
Valuation
- Price/Sales (Trailing 12 Mt.) 106.55
- Price/Book (Most Recent Quarter) 3.68
- Enterprise Value Revenue 137.46
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.19
- Next Year EPS Estimate -$0.21
- Next Quarter EPS Estimate -$0.05
- Operating Margin -921%
- Return on Assets -15%
- Return on Equity -45%
- Revenue 2.33 million
- Earnings Per Share -$0.94
- Revenue Per Share $0.02
- Gross Profit 1.64 million
- Quarterly Earnings Growth 124.5%
Highlights
- Market Capitalization 366.14 million
- EBITDA -13860000
- Analyst Target Price $2.5
- Book Value Per Share $0.51
Share Statistics
- Shares Outstanding 216.01 million
- Shares Float 215.41 million
- % Held by Insiders 91%
- % Held by Institutions 8.1%
- Shares Short 10.23 million
- Shares Short Prior Month 12.96 million
- Short Ratio 0.5
- Short % of Float 5%
- Short % of Shares Outstanding 5%
Technicals
- Beta -6.14
- 52 Week High $7.45
- 52 Week Low $0.76
- 50 Day Moving Average 1.92
- 200 Day Moving Average 1.75
Dividends
- Dividend Date 2018-06-11
- ExDividend Date N/A
- Dividend Yield 0%
iBio, Inc (IBIO) Dividend Calendar:
IBIO's last dividend payment was made to shareholders on June 11, 2018.
iBio, Inc (IBIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
iBio, Inc (IBIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 999000 | 999000 |
| Income Before Tax | N/A | N/A | N/A | -4.68 million | -4.68 million |
| Selling General Administrative | N/A | N/A | N/A | 3.16 million | 3.16 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | -3.5 million | -3.5 million |
| Operating Income | N/A | N/A | N/A | -4.06 million | -4.06 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | 96000 | 96000 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | N/A | N/A | N/A | -4.68 million | -4.68 million |
| Net Income Applicable to Common Shares | -8.13 million | -7.53 million | -3.6 million | -4.74 million | -4.74 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -820000 | N/A | -96000 | N/A |
| Change to Liabilities | -452000 | -259000 | 82000 | 82000 | -6000 |
| Total Cash Flow from Investing Activities | -6.6 million | -820000 | -96000 | -96000 | -208000 |
| Net Borrowings | -73000 | -661000 | -800000 | -800000 | N/A |
| Total Cash Flow from Financial Activities | N/A | 49.76 million | N/A | 10.29 million | 5.15 million |
| Change to Operating Activities | 251000 | -53000 | 38000 | 38000 | -85000 |
| Change in Cash | N/A | 45.07 million | N/A | 6.4 million | 1.53 million |
| Total Cash from Operating Activities | -7.07 million | -3.87 million | -3.79 million | -3.79 million | -3.41 million |
| Depreciation | N/A | 563000 | N/A | 558000 | 562000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | 149000 | -149000 |
| Other Cash Flow from Financing Activities | -1.53 million | -1.79 million | -321000 | -321000 | -60000 |
| Change to Net Income | 350000 | 218000 | 63000 | 63000 | 35000 |
| Capital Expenditures | N/A | 820000 | N/A | 96000 | 202000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 38.26 million | N/A |
| Total Stockholder Equity | N/A | N/A | N/A | 3.97 million | N/A |
| Other Current Liabilities | 1.23 million | 1.37 million | 1.81 million | N/A | 3.97 million |
| Total Assets | N/A | N/A | N/A | 42.22 million | N/A |
| Common Stock | 212000 | 180000 | 140000 | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | 107000 |
| Retained Earnings | -166.08 million | -157.95 million | -150.42 million | -146.88 million | -146.88 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | 1.54 million | 24000 | 24000 | N/A | 24000 |
| Cash | N/A | N/A | N/A | 10.04 million | 10.04 million |
| Total Current Liabilities | 6.1 million | 5.05 million | 5.24 million | 6.18 million | 6.18 million |
| Other Stockholder Equity | -53000 | -40000 | -33000 | N/A | -33000 |
| Property, Plant & Equipment | 31.8 million | 31.04 million | 31.27 million | N/A | 30.69 million |
| Total Current Assets | 110.88 million | 84.96 million | 61.75 million | 10.3 million | 10.3 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 106.15 million | 78.82 million | 55.47 million | N/A | 2.76 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 1.07 million | 843000 | 798000 | N/A | N/A |
| Accounts Payable | 2.41 million | 1.6 million | 1.76 million | 547000 | 547000 |
iBio, Inc (IBIO) Chart:
iBio, Inc (IBIO) News:
Below you will find a list of latest news for iBio, Inc (IBIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
iBio, Inc (IBIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest IBIO Trades:
iBio, Inc (IBIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-11-03 | 8-K (Current report) | |
| 2020-11-03 | DEF 14A (Other definitive proxy statements) | |
| 2020-10-28 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 10-K/A (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-10-23 | PRE 14A (Other preliminary proxy statements) | |
| 2020-10-22 | 8-K (Current report) | |
| 2020-10-16 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-16 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-16 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 8-K (Current report) | |
| 2020-10-13 | 8-K/A (Current report) | |
| 2020-10-13 | 8-K (Current report) | |
| 2020-10-13 | 10-K (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-10-09 | 8-K (Current report) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-10-05 | 3 (Initial statement of beneficial ownership of securities) | |
iBio, Inc (IBIO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of iBio, Inc (IBIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 91%
Institutional Ownership: 810%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-11 | Capital LTD Eastern | 10% Share Holder | Sell | 15,864,436.00 | 2.92 | 46,330,498.89 | 8,629,693.00 | |
| 2020-08-10 | Capital LTD Eastern | 10% Share Holder | Sell | 7,264,864.00 | 3.91 | 28,429,592.29 | 24,494,129.00 | |
| 2020-08-07 | Capital LTD Eastern | 10% Share Holder | Sell | 1,355,604.00 | 3.83 | 5,185,591.98 | 31,758,993.00 | |
| 2020-08-06 | Capital LTD Eastern | 10% Share Holder | Sell | 2,768,137.00 | 4.18 | 11,570,535.85 | 33,114,597.00 | |
| 2020-08-05 | Capital LTD Eastern | 10% Share Holder | Sell | 900,000.00 | 4.46 | 4,013,550.00 | 35,882,734.00 | |
| 2020-08-04 | Capital LTD Eastern | 10% Share Holder | Sell | 600,000.00 | 4.39 | 2,636,640.00 | 36,782,734.00 | |
| 2020-06-04 | ROBERT L ERWIN | President | Buy | 28,268.00 | 0.93 | 26,289.24 | 108,108.00 | |
| 2020-06-04 | ROBERT L ERWIN | President | Sell | 28,268.00 | 1.71 | 48,338.28 | 108,108.00 | |
| 2020-06-02 | ROBERT L ERWIN | President | Buy | 96,124.00 | 0.93 | 89,395.32 | 136,376.00 | |
| 2020-06-02 | ROBERT L ERWIN | President | Sell | 96,124.00 | 1.62 | 155,720.88 | 136,376.00 | |
| 2020-05-27 | James P. Mullaney | Chief Financial Officer | Buy | 11,250.00 | 0.93 | 10,462.50 | 0.00 | |
| 2020-05-27 | James P. Mullaney | Chief Financial Officer | Sell | 11,250.00 | 1.61 | 18,112.50 | 0.00 | |
| 2018-07-12 | Capital LTD Eastern | 10% Share Holder | Buy | 2,200,000.00 | 0.90 | 1,980,000.00 | 8,457,734.00 | |
| 2018-06-26 | Capital LTD Eastern | 10% Share Holder | Buy | 1,683,334.00 | 0.90 | 1,515,000.60 | 6,257,734.00 | |